Health Condition 1: L400- Psoriasis vulgaris
Conditions
Interventions
Intervention1: Intralesional methotrexate: Intralesional injection to be given at site of chronic plaque psoriasis,
1 plaque will be injected per sitting
Dose: 25mg/ml per plaque per sitting
Frequency
Sponsors
Sampath V
Eligibility
Inclusion criteria
Inclusion criteria: 1) All patients with clinical features of chronic Plaque psoriasis with less than 5 Plaques 2) Patients who have given consent for the study and are willing to come for regular follow up at the psoriasis clinic. 3) Patients who had not been on any systemic and topical anti psoriatic medications for at least the past 2 months will be enrolled.
Exclusion criteria
Exclusion criteria: 1) Patients with unstable psoriasis 2) Pregnant and Lactating Women 3) Patients of Psoriasis vulgaris with history of Hypersensitivity to MTX or Triamcinolone. 4) Patients with bleeding disorders and on anti-coagulant therapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1.To compare the efficacy of intralesional Methotrexate (MTX) and Triamcinolone in the treatment of Chronic plaque psoriasis both clinically and using Dermoscopy.Timepoint: 6 weeks,12 weeks,24 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| 2. To compare the common side effects of Intralesional Methotrexate and Triamcinolone Acetonide in Chronic Plaques Psoriasis.Timepoint: 6 weeks,12 weeks,24 weeks | — |
Countries
India
Contacts
Public ContactRaghul kumar J
Madras medical college
Outcome results
None listed